What is Memantine Used For?
By
Frances Gatta
| May 19th, 2023
Alzheimer’s is so far incurable, but there are medications out there that can help manage symptoms and improve quality of life for patients and…
Little-Known Cuban Alzheimer’s Drug Goes to Human Trials in Canada
By
Simon Spichak, MSc
| May 17th, 2023
Since the United States imposed an embargo on Cuba in 1961, the island nation has built a robust healthcare system on their own, with…
FDA Approves the First Drug for Alzheimer’s Agitation: Rexulti
By
Simon Spichak, MSc
| May 15th, 2023
As many as half of people who develop Alzheimer’s dementia experience the symptom of agitation, which can lead to behaviors like pacing, restlessness, and…
Sneak Peek of Trial Data for Alzheimer’s Drug Donanemab
By
Simon Spichak, MSc
| May 4th, 2023
After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…
Why Is This New Generation of Alzheimer’s Drugs Such a Big Deal?
By
Simon Spichak, MSc
| April 18th, 2023
Despite decades of study, the underlying cause of Alzheimer’s continues to evade scientists. Because it’s such a mystery, there are only six drugs approved for…
On the Verge of Full FDA Approval, New Details About Leqembi Death
By
Simon Spichak, MSc
| April 14th, 2023
In June, the Food and Drug Administration will decide whether to grant full approval to Biogen and Eisai’s anti-amyloid Alzheimer’s drug Leqembi (generic name…
Filling the Void: The Race to Treat Later-Stage Alzheimer’s
By
Simon Spichak, MSc
| April 12th, 2023
As Julie Fleming’s father slipped into the later stages of Alzheimer’s dementia, she could only watch as his computer skills and interests faded. “The…
Medicare Stands Firm: No Public Coverage for New Alzheimer’s Drugs
By
Simon Spichak, MSc
| March 7th, 2023
UPDATE: 3 March 2024, 8:21 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Leqembi Clinical Trials Aren’t Over—Half of Participants Will Get the Drug for Free
By
Simon Spichak, MSc
| February 1st, 2023
Eisai and Biogen’s new anti-amyloid drug Leqembi was recently approved through the FDA’s accelerated pathway. Now, it’s on the market with a price tag…
How to Manage Alzheimer’s Symptoms
By
The Being Patient Editorial Team
| January 30th, 2023
Alzheimer’s disease is a progressive neurodegenerative condition that affects more than one in every nine Americans over the age of 65. Managing its symptoms…
FDA Declines Rush Request for Alzheimer’s Drug Donanemab
By
Alexandra Marvar
| January 23rd, 2023
According to drugmaker Eli Lilly, the FDA has rejected the company’s application for the FDA’s “Accelerated Approval” designation for experimental Alzheimer’s drug donanemab. The…
A Trial Participant’s Inside Look at New Alzheimer’s Drug Leqembi
By
Katy Koop
| January 13th, 2023
Gordon Van Slyke’s mother and sister both passed away of early onset Alzheimer’s when they were in their early 60s. When he decided to…
Phil’s Journal: Another Alzheimer’s Drug, Lecanemab, Wins Early Approval—So, What Now?
By
Phil Gutis
| January 6th, 2023
UPDATE: 3 March 2024, 8:16 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Lecanemab Approved: New Disease-Modifying Alzheimer’s Drug Leqembi on the Market
By
Alexandra Marvar, Deborah Kan and Simon Spichak
| January 6th, 2023
Update: As of July 6, 2023, the drug has full, traditional FDA approval. Today, the Food and Drug Administration approved Leqembi (generic name lecanemab), a…
On the Brink of a Lecanemab FDA Decision, What Do We Know About the Drug’s Safety?
By
Simon Spichak, MSc
| January 5th, 2023
Drugmakers Eisai and Biogen took their anti-amyloid Alzheimer’s treatment, lecanemab, to the finish line. By clearing amyloid plaques in the brains of people with…